NCT02497300
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
See it on ClinicalTrials.gov ↗19 people
57.9%
42.1%
11 womenmiddle line = equal numbers8 men
- Phase
- PHASE2
- Paid for by
- University of Alabama at Birmingham
- Finished
- 2021-07
- Health conditions
- Chronic Kidney Disease, Albuminuria
- Who could join
- Anyone
- Ages
- 18 Years – 65 Years
- Average age
- mean 47.6 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Black / African American 68.4% · White 31.6% · American Indian / Alaska Native 0% · Asian 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0% · Not reported 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or breast feeding woman”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or breast feeding woman”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of arrhythmia, including atrial fibrillation”
- No diabetes
Women with diabetes were turned away.
“Diabetes mellitus (DM) type 1”
Study titles and rules are shown in their original English.